



Genomic Valley Biotech Limited

Regd. Off: 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman,
P.O. Tandaheeri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507
CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542

Email: genomicvalley@gmail.com; Visit: <http://www.genomicvalley.com>

Dated: 05th November, 2018

To,
BSE Limited,
PhirozeJeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)
Sub: Compliance under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Filing of Un-Audited Financial Results for the Quarter and Half Year ended 30th September, 2018

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Un-Audited Financial Results of the Company for the Quarter and Half Year ended 30th September, 2018 duly approved by the Board of Directors of the Company, at its meeting held today, the 05th day of November, 2018. The Meeting of Board of Directors of the Company commenced at 11:45 A.M. and concluded at 02:30 P.M.

We are also enclosing a copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to kindly take the same into your records.

Thanking you.

Yours faithfully,

For and on behalf of
Genomic Valley Biotech Limited

Hitesh



Hitesh Kumar
Company Secretary & Compliance officer

Encl: A/A



A.K. Khattar & Associates
Chartered Accountants

112-A, Ground Floor, DDA Complex,
Jhandewalan Extn-1, New Delhi - 110055
Ph: 011-43570260 E.mail:akkhattar112@gmail.com

LIMITED REVIEW REPORT

To,

The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- KherkaMusalman,
P.O. Tandaheri, Tehsil-Bahadurgarh,
Distt-Jhajjar, Haryana-124507

Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter and Half Year ended on 30th September, 2018

We have reviewed the accompanying statement of unaudited financial results for the quarter and half year ended September 30, 2018 ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.


This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
A. K. Khattar & Associates
Chartered Accountants




(A. K. Khattar)
(Prop.)
(Membership No.-084960)

Place: Delhi
Date: 05/11/2018

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the quarter and half year ended
30 September 2018

Highlights of the Un-Audited Financial Results as compared to the previous year are:

In Rs.

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous period ended	Previous year ended
		30-Sep-18	30-Jun-18	30-Sep-17	30-Sep-18	30-Sep-17	31-Mar-18
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue From Operations	2012512	21,08,195	13,51,170	41,20,707	26,25,000	59,44,430
II	Other Income	-	-	5,606	-	1,05,606	1,24,688
III	Total Revenue (I+II)	20,12,512	21,08,195	13,56,776	41,20,707	27,30,606	60,69,118
IV	Expenses						
	Cost of materials consumed	103645	47,116	48,294	1,50,761	1,65,214	4,52,801
	Purchases of Stock-in-Trade	-	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
	Employee benefits expense	880023	8,92,644	8,48,750	17,72,667	16,38,684	33,56,398
	Financial costs	-	-	-	-	-	-
	Depreciation and amortization expense	4,63,360	4,63,360	1,84,037	9,26,720	3,68,903	7,57,218
	Other expenses	463977	6,39,611	2,42,364	11,03,588	4,97,870	11,29,825
	Total Expenses (IV)	19,11,005	20,42,731	13,23,445	39,53,736	26,70,671	56,96,242
V	Profit / (Loss) before exceptional item and tax (III-IV)	1,01,507	65,464	33,331	1,66,971	59,935	3,72,876
VI	Exceptional Item	-	-	-	-	-	2,13,000
VII	Profit/loss before Tax (V-VI)	1,01,507	65,464	33,331	1,66,971	59,935	5,85,876
VIII	Tax expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	2,44,971
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	1,01,507	65,464	33,331	1,66,971	59,935	3,40,905
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	1,01,507	65,464	33,331	1,66,971	59,935	3,40,905
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	1,01,507	65,464	33,331	1,66,971	59,935	3,40,905
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	30,54,500	30,54,500	30,54,500	61,09,000	30,54,500	30,54,500
XVII	Earning Per Equity Share (for continuing operation):						
	1) Basic	0.03	0.02	0.01	0.03	0.02	0.11
	2) Diluted	0.03	0.02	0.01	0.03	0.02	0.11
XVIII	Earning Per Equity Share (for discontinued operation):						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):						
	1) Basic	0.03	0.02	0.01	0.03	0.02	0.11
	2) Diluted	0.03	0.02	0.01	0.03	0.02	0.11



Statement of Asset and Liabilities

Particulars	Current half year ended	Previous year ended
	30-09-2018	31-03-2018
	Un-Audited	Audited
	Standalone	Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	408,08,704	412,05,043
Capital work in progress	48,67,459	37,67,076
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	-	-
Loans	207,50,000	206,00,000
Security Deposits	4,37,788	2,87,788
Other financial assets	-	-
Deferred tax assets (Net)	-	-
Other non current assets	-	-
Total Non-Current Assets	668,63,951	658,59,908
Current Assets		
Inventories	4,15,099	3,31,798
Financial Assets:	-	-
Investments	-	-
Trade Receivables	7,39,301	2,32,437
Cash and Cash equivalents	31,760	24,225
Other Balances with banks	60,470	89,247
Loans	-	-
Other financial assets	-	-
Other Current assets	1,70,838	2,04,961
Total Current Assets	14,17,468	8,82,668
Total Assets	682,81,419	667,42,576
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	305,45,000	305,45,000
Other Equity	149,07,238	147,40,266
Total Equity	454,52,238	452,85,266
Non Current Liabilities		
Financial liabilities		
Borrowings	75,00,000	75,00,000
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	1,27,351	1,27,351
Provisions	-	-
Other Non Current liabilities	-	-
Total Non Current Liabilities	76,27,351	76,27,351
Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	25,000	75,000
Other Financials liabilities	-	-
Provisions	3,65,240	2,61,680
Other Current liabilities	148,11,591	134,93,279
Total Current Liabilities	152,01,831	138,29,959
TOTAL EQUITY AND LIABILITIES	682,81,419	667,42,576

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on November 05, 2018. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



Yogesh Agrawal

Yogesh Agrawal
Managing Director)
DIN-01165288

Place : Delhi
Dated : 05-11-2018

Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063